Governance Positive

2026-08-21 13:41

- The 37th Annual General Meeting (AGM) of Venus Remedies Limited was held on August 20, 2026. All 12 resolutions, including the adoption of FY26 financial statements and the declaration of a final dividend of ₹10/- per equity share, were passed with requisite majority.

Governance Neutral

2026-08-21 12:58

- Members approved the alteration of Memorandum and Articles of Association (MOA & AOA) at the AGM on August 20, 2026. - Revisions align the Object Clause with the Companies Act, 2013, and update business practices. - Principal business activities in the pharmaceutical sector remain unchanged.

Governance Positive

2026-08-21 12:57

- The 37th Annual General Meeting (AGM) of Venus Remedies Limited was held on August 20, 2026. All proposed resolutions were passed with the requisite majority. A final dividend of ₹10/- per equity share for FY26 was declared. Directors Mr. Ashutosh Jain and Mr. Peeyush Jain were re-appointed, while Mr. Saransh Chaudhary was appointed as Executive Director and Dr. Gurminder Singh as Non-Executive Independent Director.

Governance Neutral

2026-08-20 17:37

- At the 37th Annual General Meeting on August 20, 2026, shareholders approved the appointment of Mr. Saransh Chaudhary as Executive Director and Dr. Gurminder Singh Bedi as Non-Executive Independent Director, both for 5 years from May 26, 2026. They also approved the re-appointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director for 5 years from October 1, 2026, and Dr. (Mrs.) Savita Gupta as Non-Executive Independent Director for her 2nd term of 5 years from December 29, 2026.

Governance Positive

2026-08-20 16:12

- The 37th Annual General Meeting (AGM) of Venus Remedies Limited was held on August 20, 2026, via Video Conferencing/other Visual Audio Means (VC/OVAM). - Shareholders adopted the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. - A final dividend of Rs. 10/- per equity share (100% on face value of ₹10/-) was declared. - Resolutions included the re-appointment of directors, appointment of new executive and independent directors, ratification of cost auditor remuneration, and alteration of Memorandum and Articles of Association. - The Chairman provided an overview of the Company's performance for FY 2025-2026 and outlined future outlook and growth prospects.

Governance Positive

2026-07-24 18:53

- 37th Annual General Meeting (AGM) to be held on Thursday, August 20, 2026, at 11:30 a.m. via video conferencing. - Record date for dividend is August 7, 2026. - Proposed dividend of ₹10/- per equity share (100% on face value) for FY 2025-26. - Agenda includes adoption of financial statements for FY 2025-26, re-appointment of directors, and amendments to the Memorandum and Articles of Association to expand business activities, including into biopharmaceutical, digital platforms, and ESG initiatives.

Governance Positive

2026-07-24 18:41

- The 17th Annual General Meeting (AGM) will be held on Wednesday, June 24, 2026, at 12:00 Noon (IST) via Video Conferencing. - A final dividend of ₹5.20 per equity share for FY26 has been declared. - Mr. Divya Sehgal, Nominee Director, is not offering himself for re-appointment. - Ms. Geeta Dutta Goel and Mr. Anuj Srivastava are proposed for re-appointment as Non-Executive Independent Directors. - M/s. Batliboi & Purohit are proposed to be appointed as Joint Statutory Auditors for three years from the 17th AGM. - Approval is sought to increase borrowing powers up to ₹20,000 crore and to create charges on the Company's assets to secure these borrowings.

Governance Positive

2026-07-24 18:26

- 37th Annual General Meeting (AGM) scheduled for Thursday, August 20, 2026, via Video Conferencing. - Record date for dividend is August 7, 2026. - Final dividend of ₹10/- per equity share declared for FY 2025-26. - Resolutions include re-appointment and appointment of directors, ratification of cost auditor, and proposed alterations to the Memorandum and Articles of Association.

Financials Positive

2026-07-20 18:47

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹178.86 Cr vs ₹137.18 Cr (▲30.38% YoY) - EBITDA ₹36.81 Cr vs ₹18.80 Cr (▲95.80% YoY) - PAT ₹22.97 Cr vs ₹9.60 Cr (▲139.27% YoY) - EBITDA Margin 20.28% vs 13.37% (▲691bps) - The Board approved alterations to the Memorandum of Association (MOA) to align with business practices, subject to shareholder approval. - The audit report highlights that a wholly-owned subsidiary, Venus Pharma GmbH, is currently facing financial challenges, with the parent company reiterating its intention to provide support.

Financials Positive

2026-07-20 18:42

- Consolidated Revenue ₹178.86 Cr vs ₹137.18 Cr (▲30.38% YoY) - EBITDA ₹36.81 Cr vs ₹18.80 Cr (▲95.80% YoY) - PAT ₹22.97 Cr vs ₹9.60 Cr (▲139.27% YoY) - EBITDA Margin 20.58% vs 13.70% (▲688bps) - The Board also approved the alteration of the Memorandum of Association to align object clauses with current business practices and proposed activities in the pharmaceutical sector. - Auditors noted an emphasis of matter regarding outstanding share application money in the subsidiary, Venus Pharma GmbH, which is facing financial challenges; management intends to provide support and recover the amount.

Financials Positive

2026-07-20 18:36

- Consolidated Revenue ₹178.86 Cr vs ₹137.18 Cr (▲30.38% YoY) - EBITDA ₹36.81 Cr vs ₹18.80 Cr (▲95.80% YoY) - PAT ₹22.97 Cr vs ₹9.60 Cr (▲139.27% YoY) - EBITDA Margin 20.58% vs 13.70% (▲688bps) - Board approved alteration of Memorandum of Association to align object clause with current business practices and proposed activities, maintaining the principal business in the pharmaceutical sector.

Business Update Neutral

2026-07-18 17:28

- Venus Remedies Limited has undertaken an awareness campaign through its official social media handles (Instagram, Facebook, LinkedIn, and X) to encourage shareholders to update their KYC details.

Governance Neutral

2026-07-09 16:01

- Board meeting scheduled for July 20, 2026. - To consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. - Trading window closed from July 01, 2026 until 48 hours post results.

Routine Neutral

2026-06-25 17:05

- The trading window for dealing in the Company's securities will remain closed for all Designated Persons from July 1, 2026. - It will reopen 48 hours after the declaration of unaudited financial results for the period ending on June 30, 2026. - This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Routine Neutral

2026-06-16 12:55

- Venus Remedies Limited has disseminated social media communications to shareholders regarding the updation of KYC details. - The company shared links to its posts on Instagram, Facebook, LinkedIn, and X for awareness.

Business Update Positive

2026-06-04 16:25

- Venus Remedies Limited secured renewal of its in-house R&D recognition from the Department of Scientific and Industrial Research (DSIR). - This renewal confirms VMRC meets R&D conditions and supports work on antimicrobial resistance, including USFDA QIDP designated VRP-034.

Financials Positive

2026-05-26 22:16

Standalone Revenue for Q4 FY26 was ₹259.01 Cr vs ₹196.74 Cr (▲31.65% YoY), EBITDA was ₹64.07 Cr vs ₹29.32 Cr (▲118.52% YoY), and PAT was ₹43.45 Cr vs ₹14.79 Cr (▲193.78% YoY). EBITDA Margin expanded to 24.73% from 14.90% (▲983bps). The Board also recommended a final dividend of ₹10 (100%) per equity share for FY26.

Financials Positive

2026-05-26 22:16

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.59% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY) for the quarter ended March 31, 2026. EBITDA Margin expanded to 24.73% vs 14.90% (▲983bps). The Board also recommended a final dividend of ₹10 (100%) per equity share for the financial year 2025-26.

Financials Positive

2026-05-26 22:11

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.52% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY). EBITDA Margin 24.74% vs 14.90% (▲984bps). The Board also recommended a final dividend of ₹10 (100%) per equity share for FY2025-26.

Financials Positive

2026-05-26 22:08

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.52% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY). EBITDA Margin 24.73% vs 14.90% (▲983bps). The Board also recommended a final dividend of ₹10/- per equity share (100%) for FY 2025-26, scheduled to be paid within 30 days of the 37th Annual General Meeting (August 20, 2026).

Financials Positive

2026-05-26 22:06

Consolidated Revenue ₹259.40Cr vs ₹197.66Cr (▲31.24% YoY), EBITDA ₹68.37Cr vs ₹35.77Cr (▲91.15% YoY), PAT ₹47.49Cr vs ₹21.00Cr (▲126.14% YoY). EBITDA Margin 26.36% vs 18.10% (▲826bps). The Board also recommended a final dividend of ₹10/- (100%) per equity share for FY 2025-26, subject to shareholder approval.

Financials Positive

2026-05-26 21:56

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.52% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY). EBITDA Margin 24.73% vs 14.90% (▲983bps). The board also recommended a final dividend of ₹10/- (100%) per equity share for FY 2025-26.

Business Update Positive

2026-05-22 11:56

Venus Remedies Limited received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor, a specialty oncology therapy for autologous transplantation. This is the company's first global approval for Plerixafor and its first Marketing Authorization for a specialty oncology therapy, enabling commercialization in Saudi Arabia. This move advances the company's shift into higher-value specialty injectables in regulated markets, with the Saudi Arabian pharmaceutical market projected to grow from USD 12.1 billion in 2026 to USD 17.1 billion by 2033.

Routine Neutral

2026-05-21 17:30

Venus Remedies Limited informed the stock exchanges about social media communications made on its official handles (Instagram, Facebook, LinkedIn, and X) regarding awareness to shareholders for updation of KYC details with the company, as per Regulation 30 of SEBI (LODR) Regulations, 2015.

526953

Venus Remedies Ltd

Price Chart

Filing History

Unlock Full History